OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
June 01, 2009
Pharma vet Hans Bishop readily admits to being ruthless in his career.
Jennifer Spear Smith may be soft-spoken and petite, but she is loud, clear, and stands tall for one part of industry that she is clearly passionate about: continuing medical education (CME).
I started off as a pathologist at Boehringer-Ingelheim in Germany.
I got my first taste of this industry as an intern at Schering-Plough's Managed Care group.
My first introductions to medically relevant biology and chemistry began when I worked with Harvard professor Greg Verdine to figure out how enzymes recognized and repaired damaged DNA.
I started my career as a medical liaison. It was a wonderful opportunity to shape how companies and physicians further scientific understanding of difficult medical problems, focus on key research questions, and address unmet patient needs.
When Pfizer discontinued Exubera, its disastrously unsuccessful inhaled insulin, in 2007, the soul searching wasn't limited to Manhattan's East 42nd Street.
With staggering year-over-year growth, biosimilars are "the future of medicine." Marketers must position their companies for the inevitable changes.
The United States needs a new focus on educating its future labor force; and it needs parents to take the main role.
I have had the tremendous good fortune of strong leadership throughout my career.
I joined Merck in 1996 as a customer account representative, processing pharmaceutical and vaccine orders for our direct customers.
Prior to joining Exelixis, I was an investment banker at Goldman Sachs, focusing on M&A and corporate finance.
It's hard to believe that Michelle Dipp has been in the industry for only five years considering her significant impact thus far on it.
FDA slaps down Cheerios and forces pharma companies that use Google to make technical changes no consumer will ever notice. Big whoop.
Our second annual Emerging Leadership Awards cast the spotlight on 27 young rising stars most notable for their dedication and contribution to the pharma industry. Here's a closer look at why.
I've always loved the life sciences, and have been fortunate to have my career take place during a time of profound advances in biology.
If Carrolee Barlow has her way, the next new class of antidepressants will be branded BCI for BrainCells, Inc., the hot young San Diego biopharma riding the wave of neurogenesis.
Even in our crowd of underage overachievers, Luca Santarelli, MD, PhD, is a standout.
The P4P movement is here. Pharma marketers, it's time to take note.
A multi-phase implementation strategy can debunk the myth that social media won't work for pharma.
There is increasing importance of differentiation in the pharmaceutical industry, especially given the political, regulatory, and financial challenges we face.
People define "work" differently. For some, it's making useful objects that you can see and touch.
I worked my way through college in the emergency room. It taught me a lot about life, death, and human suffering.
The third annual audit reveals how pharma's "other half" performs.
I began my career with an interest in medicine and pharmaceutical sciences.
The catalyst for innovation in the current environment is that people are living longer and the industry is not equipped to handle the significant burden that will place on the system.
The Primary Care Business Unit at Pfizer has taken some major steps to respond to the needs of our customers.
I started out as a cardiovascular primary care sales rep with Merck in the UK.
At 22, Stephanie Bova left the United States to teach English in Japan.
In 1990, Don Sawyer entered industry like many others do: as a sales representative.